This site is intended only for healthcare professionals in the United States.
Are you a U.S. healthcare professional?

You are now leaving the AcelRx DSUVIA.com website

You are being redirected to a third-party site over which AcelRx has no control. AcelRx is not responsible for the content found on third-party sites and cannot be held liable for damages incurred from these third-party sites. Be sure to review the Privacy and Security policies of any third-party site before you provide personal or confidential information.
Would you like to continue?

Real-World
Outpatient Study

Opioid use and recovery time in patients receiving
DSUVIA in an ambulatory surgery setting1

Please see Indications and Usage, Limitations of Use, and Important Safety Information, including BOXED WARNING, below.

DSUVIA—administered prior to outpatient surgery—resulted in significantly less opioid use and shorter PACU stays1

study design

In a prospective medication use evaluation study (N=127), one dose of DSUVIA was administered 30 minutes prior to surgery in patients undergoing outpatient procedures in an ambulatory surgery setting. Perioperative opioid use and time in the PACU were compared with historical controls with nearly identical baseline demographics.1

  • Patient demographics: For the DSUVIA group vs controls, mean age (years) was 54.2 vs 52.1, mean body-mass index (kg/m2) was 32.2 vs 32.7, and mean length of surgery (minutes) was 37.3 vs 40.71
  • Surgery type: Both groups underwent nearly identical surgeries performed by the same surgeon. More than 75% of procedures were abdominal in nature (e.g., cholecystectomy, hernia repair)1
  • Primary endpoints: The use of opioids during and after surgery (administered as needed) and postoperative recovery time (from admission to discharge from PACU Phase 1)1
Chart: 46-percent reduction

Pre- and intraoperative opioid use was reduced by 46% with DSUVIA1

Fewer DSUVIA-treated patients required intraoperative IV opioids, and patients taking DSUVIA used a smaller dose of pre- and intraoperative opioids vs controls.1

Control (n=80) DSUVIA (n=47)
Patients receiving intraoperative IV opioids 97.5% 61.7%*
Pre- and intraoperative total opioid dose (MME; Mean ± SEM) 20.0 ± 1.3 mg 10.9 ± 1.0 mg


IV Acetaminophen Use Was Significantly Reduced With DSUVIA1 Fewer DSUVIA-treated patients received supplemental IV acetaminophen, which was assessed as a secondary endpoint after early observations of decreased intra- and postoperative opioid requirements.1 Patients receiving supplemental IV acetaminophen
Control (n=80) DSUVIA (n=47)
90% 38%*


*P<0.001 via chi square test.1

Includes MME of 5 mg IV morphine in the DSUVIA group to account for preoperative DSUVIA dosing as demonstrated by Miner et al.2

P<0.001 via Student’s t-test.1

MME=morphine milligram equivalents; PACU=postanesthesia care unit; SEM=standard error of the mean.

Postoperative opioid use was reduced by 80% and discharge time was 34% faster in DSUVIA-treated patients1

Chart: 80-percent reduction

Fewer DSUVIA-treated patients required postoperative opioids, and they used a smaller dose vs controls1

Control (n=80) DSUVIA (n=47)
Patients requiring postoperative IV opioids 63.0% 10.6%*
Postoperative total opioid dose (MME; Mean ± SEM) 4.4 ± 0.5 mg 0.9 ± 0.4 mg
Chart: 34-percent faster

Patients taking DSUVIA had a shorter postoperative recovery time (from admission to discharge from the phase 1 unit in the PACU) vs controls1

Phase 1 PACU Time (minutes)

Control
54.9
DSUVIA
36.3
0 10 20 30 40 50 60 70 80


Data presented as mean ± standard error of the mean.1



*P<0.001 via chi square test.1

Includes IV and oral opioids administered in the PACU.1

P<0.001 via Student’s t-test.1

MME=morphine milligram equivalents; PACU=postanesthesia care unit; SEM=standard error of the mean.

Study Limitations:

  • This study was open-label and was partially based on a retrospective analysis of a control patient population
  • The degree to which patients were opioid naïve or opioid tolerant was not controlled, which has the potential to affect the amount of opioid required to provide sufficient analgesia
  • Outside of the required preoperative dosing of DSUVIA in the prospective group, none of the other medications reported, such as opioids and adrenergic agents, were limited by the protocol and were administered only as needed
  • Additional studies evaluating DSUVIA in other surgical specialties, painful procedures, burn dressing changes, or emergency trauma settings would be beneficial
More information on DSUVIA
 
Pivotal Safety Profile

Read about the most
common
adverse reactions
with DSUVIA
and see special precautions

 
 
Case Studies:
Recovery Room

See which types of
postoperative patients
may be right for DSUVIA

 
 
One Applicator
Is One Dose

Learn about the
single-strength dosing
and sublingual
administration of DSUVIA

 
References:
  • 1. Tvetenstrand CD, Wolff ME. Reduced opioid use and reduced time in the postanesthesia care unit following preoperative administration of sublingual sufentanil in an ambulatory surgery setting. J Clin Anesth Pain Manag. 2020;4(2):123-128.
  • 2. Miner JR, Melson TI, Leiman D, Minkowitz HS, Chiang Y, DiDonato KP, Palmer PP. Pooled phase III safety analysis of sufentanil sublingual tablets for short-term treatment of moderate-to-severe acute pain. Pain Manag. 2019;9(3):259-271.

Indications and Usage

DSUVIA is indicated for use in adults in a certified medically supervised healthcare setting, such as hospitals, surgical centers, and emergency departments, for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Limitations of Use:

  • Not for home use or for use in children. Discontinue treatment with DSUVIA before patients leave the certified medically supervised healthcare setting.
  • Not for use for more than 72 hours. The use of DSUVIA beyond 72 hours has not been studied.
  • Only to be administered by a healthcare provider.
  • Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, reserve DSUVIA for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]:
    • Have not been tolerated, or are not expected to be tolerated,
    • Have not provided adequate analgesia, or are not expected to provide adequate analgesia.

IMPORTANT SAFETY INFORMATION

WARNING: ACCIDENTAL EXPOSURE AND DSUVIA REMS PROGRAM; LIFE-THREATENING RESPIRATORY DEPRESSION; ADDICTION, ABUSE, AND MISUSE; CYTOCHROME P450 3A4 INTERACTION; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS

Accidental Exposure and DSUVIA Risk Evaluation and Mitigation Strategy (REMS) Program

Accidental exposure to or ingestion of DSUVIA, especially in children, can result in respiratory depression and death. Because of the potential for life-threatening respiratory depression due to accidental exposure, DSUVIA is only available through a restricted program called the DSUVIA REMS Program.

  • DSUVIA must only be dispensed to patients in a certified medically supervised healthcare setting.
  • Discontinue use of DSUVIA prior to discharge or transfer from the certified medically supervised healthcare setting.

Life-Threatening Respiratory Depression

Serious, life-threatening, or fatal respiratory depression may occur with use of DSUVIA. Monitor for respiratory depression, especially during initiation of DSUVIA.

Addiction, Abuse, and Misuse

DSUVIA exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient’s risk prior to prescribing DSUVIA, and monitor all patients regularly for the development of these behaviors or conditions.

Cytochrome P450 3A4 Interaction

The concomitant use of DSUVIA with all cytochrome P450 3A4 inhibitors may result in an increase in sufentanil plasma concentrations, which could increase or prolong adverse drug reactions and may cause potentially fatal respiratory depression. In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in sufentanil plasma concentration. Monitor patients receiving DSUVIA and any CYP3A4 inhibitor or inducer.

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death.

  • Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate.
  • Limit dosages and durations to the minimum required.
  • Follow patients for signs and symptoms of respiratory depression and sedation.

Contraindications

Use of DSUVIA is contraindicated in patients with:

  • Significant respiratory depression
  • Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment
  • Known or suspected gastrointestinal obstruction, including paralytic ileus
  • Known hypersensitivity to sufentanil or components of DSUVIA.

Warnings and Precautions

  • Accidental ingestion or exposure to even one dose of DSUVIA, especially in children, can result in respiratory depression and death due to an overdose of sufentanil.
  • DSUVIA is for use in adult patients only in a certified medically supervised healthcare setting. Use of DSUVIA outside of this setting can increase the risk of accidental exposure in others for whom it is not prescribed, causing fatal respiratory depression. Discontinue use of DSUVIA prior to discharge or transfer from the certified medically supervised healthcare setting. DSUVIA is not for home or pediatric use.
  • Opioids can cause sleep-related breathing disorders including central sleep apnea (CSA) and sleep-related hypoxemia. Opioid use increases the risk of CSA in a dose-dependent fashion. In patients who present with CSA, consider minimizing the use of DSUVIA and carefully monitor the patient for signs of respiratory depression. (revised per 2019 opioid class labeling).
  • DSUVIA contains sufentanil, a Schedule II controlled substance. As an opioid, DSUVIA exposes users to the risks of addiction, abuse, and misuse.
  • Profound sedation, respiratory depression, coma, and death may result from the concomitant use of DSUVIA with benzodiazepines or other CNS depressants (e.g., non-benzodiazepine sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol). Because of these risks, reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate.
  • Life-threatening respiratory depression in patients with chronic pulmonary disease or in elderly, cachectic and debilitated patients: monitor patients closely, particularly when initiating DSUVIA therapy and when DSUVIA is used with other drugs that depress respiration. Management of respiratory depression may include close observation, supportive measures, and use of opioid antagonists, depending on the patient’s clinical status.
  • A potentially life-threatening condition could result from concomitant serotonergic drug administration. Discontinue DSUVIA if serotonin syndrome is suspected. Cases of adrenal insufficiency have been reported with opioid use (usually > 1 month). Presentation and symptoms are non-specific and include nausea, vomiting, anorexia, fatigue, weakness, dizziness and low blood pressure. Confirm diagnosis with testing as soon as possible and, if confirmed, treat with physiologic replacement of corticosteroids and wean patient from opioid.
  • As with all opioids, sufentanil may produce bradycardia or hypotension in some patients. Therefore DSUVIA should be used with caution in patients with bradyarrhythmias or hypovolemia.
  • DSUVIA should not be used in patients who may be particularly susceptible to the intracranial effects of CO2 retention, such as those with evidence of increased intracranial pressure, impaired consciousness or coma.
  • Prolonged use of DSUVIA during pregnancy can result in withdrawal in the neonate, which can be life-threatening. Observe newborns for signs of neonatal opioid withdrawal syndrome and manage accordingly. Advise pregnant women using opioids for a prolonged period of this risk and ensure that appropriate treatment will be available.
  • Insufficient data are available on the use of DSUVIA in patients with severe liver or kidney impairment. DSUVIA should be used with caution in such patients due to the importance of these organs in the metabolism and excretion of sufentanil.

Adverse Reactions

Adverse reactions are described, or described in greater detail, in other sections of the Prescribing Information:

  • Life-Threatening Respiratory Depression [see Warnings and Precautions (5.3)]
  • Addiction, Abuse, and Misuse [see Warnings and Precautions (5.4)]
  • Adrenal Insufficiency [see Warnings and Precautions (5.9)]
  • Severe hypotension [see Warnings and Precautions (5.10)]
  • Gastrointestinal Adverse Reactions [see Warnings and Precautions (5.12)]
  • Seizures [see Warnings and Precautions (5.13)]
  • Neonatal Opioid Withdrawal Syndrome [see Warnings and Precautions (5.15)]

The most commonly reported adverse reactions (≥ 2% and higher than placebo) were nausea, headache, vomiting, dizziness, and hypotension.

Medical Information

For medical inquiries or to report an adverse event, other safety-related information or product complaints for a company product, please contact the AcelRx Medical Information Contact Center at 1-855-925-8476 or AcelRxMedInfo@rmpdc.org.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see full Prescribing Information and Directions for Use.

Indications and Usage

DSUVIA is indicated for use in adults in a certified medically supervised healthcare setting, such as hospitals, surgical centers, and emergency departments, for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Limitations of Use:

  • Not for home use or for use in children. Discontinue treatment with DSUVIA before patients leave the certified medically supervised healthcare setting.
  • Not for use for more than 72 hours. The use of DSUVIA beyond 72 hours has not been studied.
  • Only to be administered by a healthcare provider.
  • Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, reserve DSUVIA for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]:
    • Have not been tolerated, or are not expected to be tolerated,
    • Have not provided adequate analgesia, or are not expected to provide adequate analgesia.

IMPORTANT SAFETY INFORMATION

WARNING: ACCIDENTAL EXPOSURE AND DSUVIA REMS PROGRAM; LIFE-THREATENING RESPIRATORY DEPRESSION; ADDICTION, ABUSE, AND MISUSE; CYTOCHROME P450 3A4 INTERACTION; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS

Accidental Exposure and DSUVIA Risk Evaluation and Mitigation Strategy (REMS) Program

Accidental exposure to or ingestion of DSUVIA, especially in children, can result in respiratory depression and death. Because of the potential for life-threatening respiratory depression due to accidental exposure, DSUVIA is only available through a restricted program called the DSUVIA REMS Program.

  • DSUVIA must only be dispensed to patients in a certified medically supervised healthcare setting.
  • Discontinue use of DSUVIA prior to discharge or transfer from the certified medically supervised healthcare setting.

Life-Threatening Respiratory Depression

Serious, life-threatening, or fatal respiratory depression may occur with use of DSUVIA. Monitor for respiratory depression, especially during initiation of DSUVIA.

Addiction, Abuse, and Misuse

DSUVIA exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient’s risk prior to prescribing DSUVIA, and monitor all patients regularly for the development of these behaviors or conditions.

Cytochrome P450 3A4 Interaction

The concomitant use of DSUVIA with all cytochrome P450 3A4 inhibitors may result in an increase in sufentanil plasma concentrations, which could increase or prolong adverse drug reactions and may cause potentially fatal respiratory depression. In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in sufentanil plasma concentration. Monitor patients receiving DSUVIA and any CYP3A4 inhibitor or inducer.

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death.

  • Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate.
  • Limit dosages and durations to the minimum required.
  • Follow patients for signs and symptoms of respiratory depression and sedation.
Expand ++